Abstract: Expression of CD30 in blastoid cutaneous infiltrates typically signifies a CD30 + lymphoproliferative disorder, often requiring minimal immunohistochemical workup, if clinically consonant. However, myeloid and other hematologic malignancies often express CD30. We retrospectively examined the prevalence of CD30 expression in 41 patients (median age 59) and 55 biopsies with the diagnosis of leukemia cutis (LC) to determine whether an extensive immunohistochemical workup is warranted in all large, round cell CD30 + cutaneous infiltrates. Each patient had refractory or recurrent disease, the histologic presence of a large mononuclear cell infiltrate, and varied cytogenetics. CD30 + mononuclear cells within the infiltrate ranged from rare to many in 22 biopsies (22/55). In 18 biopsies, CD30 + cells were interpreted as lymphocytic based on morphology, strong cytoplasmic and Golgi staining for CD30, and negative CD34 and CD117 staining. One case showing 3+ staining of lymphocytes was identified as a posttransplant lymphoproliferative disorder. The second 3+ case was favored to represent a subset of CD30-positive acute myeloid leukemia. Three other cases with 1+ membranous and cytoplasmic staining were interpreted as myeloid leukemia. In conclusion, CD30 positivity in myeloid leukemia in the skin is rare and does not often exhibit the strong membranous (2+ or 3+) and/or Golgi staining seen in reactive lymphocytes. Acute myeloid leukemia or myeloid LC may occasionally show 1+ (and rarely 2-3+) cytoplasmic/ membranous or nonspecific blush nuclear CD30 labeling. Strong diffuse staining for CD30 should prompt consideration of a reactive lymphoid/lymphoproliferative process, and, when the clinical likelihood of CD30 + LC is low, may obviate the need for further immunohistochemistry.
INTRODUCTION
CD30 is a 120 kD cell membrane glycoprotein that shares sequence homology with tumor necrosis factor (TNF) receptors and is also known as TNF receptor superfamily member 8 (TNFRSF8). 1 CD30 is expressed by activated B and T cells in physiologic states, 2 and is upregulated in some autoimmune and inflammatory disorders. 3 It is also expressed in subtypes of B-and T-cell lymphoma such as classical Hodgkin lymphoma (CHL) 4 and anaplastic large cell lymphoma (ALCL), as well as a spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders (LPDs) such as lymphomatoid papulosis (LyP). In cutaneous pathology, the finding of strong CD30 expression by a mononuclear cell infiltrate raises the differential diagnosis of a CD30-positive LPD.
Leukemia cutis (LC) is defined as cutaneous infiltration by neoplastic leukocytes, either myeloid or lymphoid, that results in visible skin lesions. LC most commonly occurs in patients with acute myeloid leukemia (AML), a genetically heterogenous hematologic malignancy characterized by clonal proliferation of marrow-derived precursor cells that may involve the bone marrow, peripheral blood, and/or extramedullary tissues. Subsets of AML are associated with high-risk cytogenetic abnormalities, 5 arise from a pre-existing myelodysplastic syndrome (MDS), or occur following previous cytotoxic therapy. The frequency of LC differs widely among various subtypes of AML but is most commonly seen in AML with monocytic (13%) and myelomonocytic differentiation (10%-33%). 6 LC may also be seen in association with other myeloid malignancies such as MDS and chronic myelomonocytic leukemia (CMML), as well as lymphoid neoplasms such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). LC may present concurrently with bone marrow disease, may be the first sign of relapsed disease, or may even precede bone marrow involvement. 7 The presence of LC may be associated with higher rates of extramedullary leukemic involvement at other sites. 8 CD30 expression by myeloblasts, first demonstrated in 1993 by Masuya et al, 9 was recently identified by Zheng et al in bone marrow specimens from patients with AML and high-grade MDS. 10 Similarly, Fathi et al reported variable CD30 expression, ranging from 2% to 80%, in bone marrow samples involved by AML. 11 The expression of CD30 has 12 garnered significant clinical interest as targeted therapies to the CD30 antigen are now Food and Drug Administration-approved and increasingly used in hematologic malignancies, showing durable responses as in refractory and relapsed CHL and ALCL. Phase-II trials with anti-CD30 therapy have been conducted for the treatment of cutaneous T-cell lymphoma or mycosis fungoides, and clinical trials are ongoing. [13] [14] [15] Although the expression of CD30 by extracutaneous myeloid neoplasms has been evaluated, CD30 expression in LC derived from myeloid neoplasms has not been systematically investigated. To facilitate the distinction of cutaneous CD30-positive LPDs from cutaneous myeloid neoplasms, we examined the frequency and staining pattern of CD30 expression in myeloid LC specimens.
MATERIALS AND METHODS
The study was conducted in accordance with protocols approved by the institutional review board at our cancer center. All patients included in this study were evaluated and treated at our institution. An institutional review boardapproved pathology database search for "leukemia cutis" from 2000 to 2012 identified 41 patients with 55 skin biopsies. Three of these patients were found to have lymphoid leukemia (CLL, B-ALL, and T-ALL) and were kept in the study for comparison and demonstrative purposes. Clinical charts, pathology reports, and histologic material of these 41 patients were reviewed. Immunophenotypic and cytogenetic data were collected for bone marrow biopsy specimens, and the immunophenotypic profile of skin biopsies involved by LC was compiled. CD30 immunohistochemical stains were examined if already available or performed (BER-H2) as per routine on 5-micron-thick formalin-fixed paraffinembedded tissue sections as per the manufacturer's protocol. Histologic sections were examined for architecture and cytomorphology. CD30 expression was assessed for the presence/ absence, localization (cytoplasmic, membranous, and/or nuclear), and intensity of labeling (on a scale of 1+ to 3+).
RESULTS
The clinicopathologic characteristics of the 38 patients with myeloid LC are listed in Table 1 . These include 25 male and 13 female patients. The median age was 59 (range, 9-81) years. Of these, 37/38 had one or more bone marrow biopsies diagnostic of a myeloid neoplasm, including 30 cases of AML (79%), 5 cases of CMML (13%), 1 case of MDS (refractory anemia with excess blasts-2; 2.6%), and 1 case of biphenotypic acute leukemia (AML/T-ALL; 2.6%). In the remaining patient, a bone marrow biopsy performed before skin biopsy did not show pathologic findings. Five cases (5/38) were therapy-related MDS/AML, whereas the rest of the cases were de novo myeloid neoplasms. Three cases of lymphoid leukemia initially identified in our text search were included for proof-of-principle, including CLL, B-ALL, and T-ALL (1 case each). All patients were treated with induction chemotherapy, whereas some also received peripheral blood or double cord blood stem cell transplants.
Bone marrow biopsies, available on all 38 patients, were performed before (,30 days; 2/38), around the same time as (within 30 days; 13/38), or subsequent to (.30 days; 23/38) their first skin biopsies. Monocytic differentiation, as supported by morphologic, immunophenotypic, and/or histochemical characteristics, was noted in diagnostic bone marrow biopsies of 27/30 AML, 5/5 CMML, and 1/1 MDS cases but not in the case of biphenotypic acute leukemia (Table 1 ). Karyotype and/ or fluorescence in situ hybridization studies were normal in 23/ 38 cases (60.5%) and abnormal in 15/38 cases (39.5%). Chromosomal abnormalities included balanced translocations [t (6;11) , t (8;12) , t (11;19) , t (3;5) , t (6:22) , t (9;11) , t (1;9;11) ], trisomies (+8, +18, +21, +14), deletion/gain (25q, 27q, 26, 212, 216/16q, +1p), and others [der(12), inv(16)]. A complex karyotype (the presence of 3 or more abnormalities) was present in 5/38 cases. A total of 55 skin biopsy specimens were examined from various anatomic locations. Among the 38 patients with myeloid leukemia, 6 had more than 1 skin biopsy. Histologically, all skin biopsies showed the presence of an intermediateto large-sized mononuclear cell infiltrate.
Immunohistochemically, the cutaneous leukemic infiltrates showed the expression of CD43, CD68, myeloperoxidase, and muraminidase/lysozyme in a varying proportion of cases. Giemsa and Leider histochemical stains were also positive in a subset of cases. Most myeloid cases were CD34-negative (9) except 1 case (case 27), which was also muraminidase-positive. B-and T-cell markers were uniformly absent in myeloid cases, except in 2 cases that were CD3-positive.
Twenty-two (40.0%) of the 55 skin biopsies showed CD30 positivity by a mononuclear cell infiltrate; the intensity Fig. 2D ; Table 2 ). The diagnostic bone marrows of these 3 cases showed CMML-1, AML, and mixedphenotype acute leukemia, T cell/myeloid (1 case each). In addition, 2 (2/55) of the AML skin biopsies showed blush nuclear staining (Fig. 2E) . None of the myeloid LC cases showed diffusely strong membranous, cytoplasmic, or nuclear CD30 expression. In addition to expression by leukemic and reactive lymphoid infiltrates, CD30 immunoreactivity was also noted in rare mast cells (Fig. 2F) . Melanin, hemosiderin, and edge effects of the stained slides were confounding factors in the analysis of staining patterns.
No associations could be made between cytogenetic findings and CD30 expression in the 4 myeloid LC cases showing membranous CD30 expression. Two of the 4 cases had a normal karyotype, whereas the other 2 had different abnormal cytogenetic findings (Table 1) . No significant associations could be made between CD30 expression, biopsy site, concurrent bone marrow, blast percentage in the marrow (when available), and other immunophenotypic findings. Three cases with CD30-positive cutaneous leukemic infiltrates showed monocytic differentiation by blasts in bone marrow (1 of CMML-1, AML, and AML/T-ALL, each) ( Table 3) .
DISCUSSION
Expression of CD30 in cutaneous mononuclear cell infiltrates often suggests the presence of a cutaneous CD30-positive T-cell LPD such as LyP or ALCL. For either diagnosis (particularly LyP), both clinical information and histologic characteristics of the CD30-positive infiltrate are often sufficient to confirm the diagnosis. The diagnosis of LyP, for example, relies on 3 parameters as follows: typical papulonecrotic or papulonodular lesions, supportive histopathologic features, and a clinical course marked by spontaneous disappearance and recurrence. In contrast, patients with ALCL often present with more systemic symptoms and clinically persistent, sometimes ulcerated nodules. CD30 is also expressed in systemic lymphomas such as peripheral T-cell lymphoma, 16 aggressive systemic mastocytosis, 17 and primary cutaneous T-cell lymphoma such as mycosis fungoides. It has been shown that 30%-70% of extracutaneous myeloid neoplasms express CD30. 11 To our knowledge, expression of CD30 in myeloid LC has not been reported.
In this study, we showed that CD30 positivity may be seen in skin biopsies involved by myeloid LC with cytoplasmic/Golgi, membranous, cytoplasmic, and blush nuclear staining patterns. Cytoplasmic/Golgi staining was mostly associated with an intervening lymphoid infiltrate consisting of reactive lymphocytes. In fact, 1 case of CLL showed strong cytoplasmic/Golgi staining and the typical membranous pattern seen in the spectrum of CD30-positive LPDs (Figs. 2A-C) . In contrast, reactive lymphocytes in AML cases showed a similar staining pattern but with much less intensity. A Golgi (perinuclear dot-like)-staining pattern has been reported in reactive lymphocytes in CHL, 18 whereas a diffuse-staining pattern is seen in some nonhematologic neoplasms. 19 We noted membranous CD30 expression in only 4 of the examined myeloid LC cases (Fig 3A, B) . The staining was generally weak, similar to reported findings in extracutaneous AML cases with monocytic differentiation. The neoplastic infiltrates in skin biopsies examined in this study were CD34-and CD117-negative in all cases, but 1 case was CD34-positive and CD117-negative. This is consistent with the presence of monocytic differentiation that was confirmed in bone marrow biopsies. CD34 and CD117 were not examined in the cases that showed membranous CD30-staining. In addition, all myeloid leukemia cases and the concomitant skin biopsies were confirmed to be of myeloid derivation based on bone marrow morphologic examination and immunophenotypic studies of myeloid markers essentially excluding the possibility of a CD30-positive LPD.
In contrast to extracutaneous AML, in which it has been suggested that cases with high-risk cytogenic abnormalities and treatment refractoriness highly express CD30, 10 no correlation was seen between CD30 expression and cytogenetic findings. All cases in our study were either relapsed and/or refractory to treatment. Our study showed no correlation between CD30 expression and the development of LC after receiving chemotherapy for primary bone marrow AML. Conversely, Zheng et al 10 reported an increased incidence of CD30 expression in patients with active disease who had been treated with chemotherapy. They also noted that contrary to peripheral blood, CD30 expression was consistently higher in bone marrow specimens, suggesting that CD30 expression in AML may be site-specific. Future studies comparing concurrent bone marrow and skin specimens might clarify this issue.
Interestingly, Zheng et al 10 also reported a correlation between blast percentage and CD30 expression and noted that in cases with low blast percentage by flow cytometry, CD30 expression was attenuated and technically difficult to assess. In this study, blast percentage of bone marrow biopsy performed at or around the time of LC presentation did not correlate with CD30 expression. The aforementioned study showed that CD30 is expressed by myeloblasts in many cases of AML with either de novo presentation or arising from MDS, whereas monoblasts or background monocytes did not express this marker. Of the 3 cases with diffuse membranous CD30 expression in our study, 2 exhibited monocytic differentiation (cases 13 and 18; Table 3 ), an observation differing from the Zheng et al's 10 study. However, this represents only a small subset of myeloid LC cases with monocytic differentiation, suggesting that CD30 expression in the bone marrow is differentially expressed compared with that in the skin.
We encountered several issues that made the qualitative assessment of CD30 expression in skin specimens challenging. One issue, of note, was the low incidence and intensity of CD30 expression in LC. In addition, reactive lymphocytes 20 and mast cells 21 express CD30, confounding the assessment of weak CD30 expression by blasts. CD30 expression by reactive T cells is of particular interest because some of the patients in this study received allogeneic stem cell transplants, and a report by Chan et al 20 showed CD30 expression in subsets of T cells involved in alloimmune responses. However, it should be noted that CD30-positive reactive lymphocytes were also present in patients who did not receive allogeneic stem cell transplants.
In summary, our study supports the use of a judiciously limited workup in the diagnosis of a cutaneous CD30-positive LPD hematolymphoid infiltrate in the characteristic clinical setting. Specifically, the vast majority of myeloid LC cases lacked CD30 expression. This is an important finding because cutaneous myeloblastic infiltrates may appear morphologically similar to a CD30 + LPD on routine histology and may show aberrant T-cell antigen expression. CD30 + LPDs may arise in patients who previously received hematopoietic stem cell transplants, 22,23 a frequently used treatment of AML. The incidence of a posttransplant lymphoproliferative disorder in transplant recipients is further increased by additional risk factors such as T-cell depletion and utilization of drugs for both prophylaxis and treatment of a graft-versus-host disease, including donor-derived lymphomas (eg, LyP). [22] [23] [24] [25] In summary, CD30 expression in myeloid LC is variable, typically weak, and may be helpful to differentiate LC from reactive lymphocytes. Further studies with a larger number of cases would be helpful to validate this finding.
